T-cell receptor and costimulatory molecule (TCR and costimulatory molecule)

The term "T-cell receptor and costimulatory molecules on T-lymphocytes" collectively refers to the central signaling and regulatory complexes that govern T-cell activation. The **T-cell receptor (TCR)** is a transmembrane heterodimer (alpha-beta or gamma-delta chains) present on the surface of T lymphocytes; it recognizes antigenic peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[1][3][5][6][7]. **Costimulatory molecules**—including CD28, CTLA-4, and PD-1—are required for full T-cell activation or regulation and modulate immune responses by providing essential secondary signals during antigen recognition[5][6]. Engagement of the TCR by peptide-MHC complexes without adequate costimulatory signaling leads to T-cell anergy or tolerance, while coordinated costimulatory input ensures robust immune function[5][6]. These targets are both therapeutically actionable: antibodies or cell therapies can modulate TCR signaling or costimulatory pathways in cancer, autoimmunity, or infection settings[7]. Because "T-cell receptor and costimulatory molecules" is a broad grouping and not a single defined molecular target, clinical and research applications typically focus on individual members, such as TCR, CD28, CTLA-4, or PD-1, each of which may have a specific canonical name, abbreviation, and associated drug or disease relevance[7]. **Note:** This entry covers a functional group. For structured databases, each key molecule (e.g., "T-cell receptor alpha/beta complex", "CD28", "CTLA-4") should be entered as a unique target with its own metadata.

Other names

TCR complex and costimulatory receptorsTCR/CD3 complex with costimulatory molecules

Immune checkpoint blockade (e.g., anti-PD-1, anti-CTLA-4 antibodies prevent inhibitory signaling to enhance T-cell activation); TCR gene transfer or TCR-mimic therapies bind specific antigens on tumor cells; Costimulatory agonists (stimulate CD28 or other costimulatory pathways)